CAI
Caris Life Sciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+34/100
Last price
27.60
▼ 2.79 (9.18%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
27.40
Prev close
30.39
Day high
32.56
Day low
27.29
Volume
4.75M
Market cap
$7.76B
P/E (TTM)
16.25
52W range
14.19 – 33.66
Day trading desk
Gap from prior close
-9.84%
Prior close 30.39
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
0.84%
27.40 – 27.63
Position in range
87%
Near session high
ATR (14D)
1.90
6.87% of price
Prior day high
30.46
PDH
Prior day low
28.30
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 4.87M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.98%
-14.9%
1M
+9.51%
+8.4%
3M
+58.52%
+54.0%
6M
+46.43%
+28.2%
YTD
+1.76%
-12.5%
1Y
-13.61%
-30.0%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CAI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+785.07K
Net buying
Buy transactions
13
1.79M shares
Sell transactions
3
1.00M shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
137.88M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 26 | DENTON JOHN RUSSEL General Counsel |
SELL | 7.50K | $238.63K | Direct |
| Sep 17, 26 | BRILLE BRIAN J. Officer and Director |
SELL | 400.00K | $12.13M | Direct |
| Sep 17, 26 | BRILLE BRIAN J. Officer and Director |
CONVERSION | 400.00K | $976.00K | Direct |
| Sep 4, 26 | SPETZLER DAVID BAXLEY PH.D. President |
SELL | 597.21K | $14.83M | Direct |
| Sep 4, 26 | SPETZLER DAVID BAXLEY PH.D. President |
CONVERSION | 1.25M | $3.05M | Direct |
| Aug 14, 26 | CASTLEMAN PETER M Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | GILLIAM JOSEPH E. Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | VACIRCA JEFF L Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | MINOR LLOYD B. Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | JOHANSEN LAURA I. Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | HALBERT JON S. Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | PHILLIPS T DANNY Director |
STOCK | 13.19K | $0 | Direct |
| Aug 14, 26 | FREDRICKSON DAVID PAUL Director |
STOCK | 13.19K | $0 | Direct |
| May 29, 26 | POSTE GEORGE H Director |
STOCK | 1.60K | $24.99K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAPT I LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
BRILLE BRIAN J. |
Officer and Director | 730.30K | Sale |
CASTLEMAN PETER M |
Director | 10.68M | Stock Award(Grant) |
HALBERT DAVID D |
Chief Executive Officer | 123.64M | Stock Award(Grant) |
HALBERT JON S. |
Director | 1.49M | Stock Award(Grant) |
JOHANSEN LAURA I. |
Director | 343.90K | Stock Award(Grant) |
KNOWLES JONATHAN KENNETH CHARLES |
Director | 308.98K | Stock Award(Grant) |
POSTE GEORGE H |
Director | 529.43K | Stock Award(Grant) |
SPETZLER DAVID BAXLEY PH.D. |
President | 1.18M | Sale |
TSSP SUB-FUND HOLDCO, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$7.76B
Enterprise value$7.42B
Revenue (TTM)$989.60M
Gross profit$691.23M
EBITDA$174.02M
Net income$105.14M
EPS (TTM)$1.69
Free cash flow$63.26M
Total cash$793.12M
Total debt$452.40M
Book value / share$2.09
Shares outstanding282.68M
Float134.87M
Short % of float11.58%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E16.25
Forward P/E75.47
PEG ratio—
Price / sales—
Price / book13.11
EV / revenue7.50
EV / EBITDA42.63
Gross margin69.85%
Operating margin10.21%
Profit margin10.62%
Return on equity20.13%
Return on assets8.77%
Debt / equity76.45
Current ratio5.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $812.03M | $412.26M | $306.13M | $258.49M | +97.0% |
| Operating revenue | $812.03M | $412.26M | $306.13M | $258.49M | +97.0% |
| Cost of revenue | $272.87M | $233.48M | $216.82M | $178.46M | +16.9% |
| Gross profit | $539.17M | $178.78M | $89.31M | $80.02M | +201.6% |
| Research & development | $101.58M | $113.92M | $116.88M | $101.27M | -10.8% |
| Selling, general & admin | $392.47M | $321.99M | $291.98M | $294.51M | +21.9% |
| Total operating expense | $494.06M | $435.90M | $408.86M | $395.78M | +13.3% |
| Operating income | $45.11M | -$257.12M | -$319.55M | -$315.76M | +117.5% |
| Net interest income | -$40.36M | -$42.90M | -$20.35M | -$25.73M | +5.9% |
| Pre-tax income | -$68.09M | -$281.89M | -$341.42M | -$320.83M | +75.8% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$68.09M | -$281.89M | -$341.42M | -$320.83M | +75.8% |
| Net income to common | -$537.96M | -$378.26M | -$462.53M | -$399.83M | -42.2% |
| Basic EPS | -3.22 | -1.36 | -1.82 | -1.57 | -136.6% |
| Diluted EPS | -3.22 | -1.36 | -1.82 | -1.57 | -136.6% |
| EBIT | -$11.23M | -$231.87M | -$309.81M | -$294.15M | +95.2% |
| EBITDA | $11.38M | -$182.95M | -$260.80M | -$245.89M | +106.2% |
| Basic shares | 167.21M | 277.93M | 254.79M | 254.79M | -39.8% |
| Diluted shares | 167.21M | 277.93M | 254.79M | 254.79M | -39.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $796.27M | $63.95M | $56.40M | $107.19M | +1,145.2% |
| Cash & short-term investments | $798.57M | $66.15M | $121.59M | $409.62M | +1,107.2% |
| Accounts receivable | $112.14M | $88.24M | $48.70M | $40.23M | +27.1% |
| Inventory | $63.63M | $39.57M | $49.00M | $46.96M | +60.8% |
| Total current assets | $997.80M | $215.73M | $242.61M | $516.04M | +362.5% |
| Property, plant & equipment | $63.17M | $67.82M | $147.51M | $138.05M | -6.9% |
| Goodwill & intangibles | $19.34M | $19.34M | $19.34M | $19.34M | 0.0% |
| Total assets | $1.13B | $343.73M | $412.90M | $717.42M | +227.5% |
| Total current liabilities | $127.14M | $165.42M | $95.14M | $136.91M | -23.1% |
| Current debt | — | $60.00M | $167.00K | $52.79M | — |
| Long-term debt | $378.45M | $319.19M | $166.11M | $169.57M | +18.6% |
| Total debt | $427.69M | $424.26M | $217.11M | $270.87M | +0.8% |
| Total liabilities | $548.36M | $2.84B | $2.56B | $2.42B | -80.7% |
| Retained earnings | -$2.55B | -$2.47B | -$2.12B | -$1.68B | -3.1% |
| Shareholder equity | $577.31M | -$2.50B | -$2.14B | -$1.70B | +123.1% |
| Working capital | $870.65M | $50.31M | $147.47M | $379.14M | +1,630.7% |
| Net tangible assets | $557.96M | -$2.52B | -$2.16B | -$1.72B | +122.2% |
| Shares issued | 284.14M | 277.93M | 277.93M | 277.93M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$68.09M | -$281.89M | -$341.42M | -$320.83M | +75.8% |
| Depreciation & amortisation | $22.61M | $48.91M | $49.00M | $48.25M | -53.8% |
| Stock-based compensation | $70.01M | $18.64M | $15.24M | $22.90M | +275.5% |
| Change in working capital | -$33.13M | -$29.07M | -$7.13M | -$22.26M | -14.0% |
| Operating cash flow | $83.16M | -$245.20M | -$276.10M | -$285.71M | +133.9% |
| Capital expenditure | -$16.26M | -$8.44M | -$22.32M | -$42.26M | -92.6% |
| Investing cash flow | -$16.26M | $52.93M | $214.77M | -$282.99M | -130.7% |
| Share buybacks | -$113.00K | $0 | $0 | — | — |
| Financing cash flow | $664.99M | $200.29M | $10.13M | $10.45M | +232.0% |
| Free cash flow | $66.89M | -$253.64M | -$298.42M | -$327.96M | +126.4% |
| End cash position | $800.04M | $68.03M | $60.01M | $111.14M | +1,076.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | +22.0% |
| Operating revenue | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | +22.0% |
| Cost of revenue | $84.12M | $74.83M | $71.97M | $69.33M | $67.71M | +12.4% |
| Gross profit | $179.60M | $141.35M | $220.91M | $147.51M | $113.69M | +27.1% |
| Research & development | $32.36M | $31.32M | $31.84M | $21.62M | $25.05M | +3.3% |
| Selling, general & admin | $120.31M | $104.75M | $100.66M | $93.24M | $106.63M | +14.9% |
| Total operating expense | $152.67M | $136.07M | $132.50M | $114.86M | $131.67M | +12.2% |
| Operating income | $26.93M | $5.28M | $88.41M | $32.64M | -$17.99M | +409.8% |
| Net interest income | -$2.41M | -$5.97M | -$4.34M | -$6.15M | -$17.59M | +59.7% |
| Pre-tax income | -$614.00K | -$644.00K | $81.96M | $24.32M | -$71.79M | +4.7% |
| Tax provision | $23.00K | -$134.00K | $0 | $0 | $0 | +117.2% |
| Net income | -$637.00K | -$510.00K | $81.96M | $24.32M | -$71.79M | -24.9% |
| Net income to common | -$637.00K | -$510.00K | $81.96M | $24.32M | -$517.20M | -24.9% |
| Basic EPS | 0.00 | 0.00 | 0.29 | 0.09 | -7.97 | — |
| Diluted EPS | 0.00 | 0.00 | 0.28 | 0.08 | -7.97 | — |
| EBIT | $8.61M | $12.16M | $93.31M | $37.83M | -$52.58M | -29.2% |
| EBITDA | $15.15M | $17.23M | $97.60M | $42.70M | -$46.17M | -12.1% |
| Basic shares | 282.89M | 282.56M | 282.22M | 282.10M | 64.92M | +0.1% |
| Diluted shares | 282.89M | 282.56M | 296.09M | 297.21M | 64.92M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $690.91M | $821.15M | $796.27M | $753.22M | $718.93M | — | -15.9% |
| Cash & short-term investments | $793.12M | $823.46M | $798.57M | $755.49M | $721.18M | — | -3.7% |
| Accounts receivable | $116.89M | $90.52M | $112.14M | $26.70M | $50.89M | — | +29.1% |
| Inventory | $123.79M | $76.29M | $63.63M | $49.30M | $40.61M | — | +62.3% |
| Total current assets | $1.06B | $1.01B | $997.80M | $854.25M | $833.32M | — | +4.3% |
| Property, plant & equipment | $95.72M | $82.67M | $63.17M | $64.00M | $61.31M | — | +15.8% |
| Goodwill & intangibles | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M | — | 0.0% |
| Total assets | $1.23B | $1.16B | $1.13B | $984.57M | $955.06M | — | +5.8% |
| Total current liabilities | $191.44M | $143.90M | $127.14M | $86.03M | $90.18M | — | +33.0% |
| Current debt | $178.00K | $173.00K | — | $164.00K | $95.00K | $60.09M | +2.9% |
| Long-term debt | $392.97M | $381.40M | $378.45M | $376.30M | $373.61M | — | +3.0% |
| Total debt | $452.40M | $430.96M | $427.69M | $426.74M | $418.98M | — | +5.0% |
| Total liabilities | $637.89M | $568.90M | $548.36M | $506.21M | $502.15M | — | +12.1% |
| Retained earnings | -$2.55B | -$2.55B | -$2.55B | -$2.63B | -$2.66B | — | -0.0% |
| Shareholder equity | $591.73M | $593.49M | $577.31M | $478.36M | $452.90M | — | -0.3% |
| Working capital | $866.39M | $870.28M | $870.65M | $768.22M | $743.14M | — | -0.4% |
| Net tangible assets | $572.39M | $574.15M | $557.96M | $459.02M | $433.56M | — | -0.3% |
| Shares issued | 282.58M | 284.26M | 284.14M | 283.72M | 282.71M | — | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$637.00K | -$510.00K | $81.96M | $24.32M | -$71.79M | -24.9% |
| Depreciation & amortisation | $6.54M | $5.07M | $4.29M | $4.87M | $6.41M | +29.1% |
| Stock-based compensation | $22.22M | $15.87M | $13.37M | $13.65M | $28.29M | +40.0% |
| Change in working capital | -$26.37M | $8.29M | -$59.10M | $14.09M | -$1.44M | -418.2% |
| Operating cash flow | $28.48M | $32.88M | $44.78M | $62.42M | $7.29M | -13.4% |
| Capital expenditure | -$22.07M | -$10.34M | -$5.09M | -$7.09M | -$1.39M | -113.5% |
| Investing cash flow | -$122.19M | -$10.34M | -$5.09M | -$7.09M | -$1.39M | -1,081.5% |
| Share buybacks | -$21.36M | $0 | -$91.00K | $0 | $0 | — |
| Financing cash flow | -$36.90M | $824.00K | $3.40M | -$21.10M | $681.40M | -4,578.5% |
| Free cash flow | $6.40M | $22.53M | $39.69M | $55.33M | $5.90M | -71.6% |
| End cash position | $692.75M | $823.39M | $800.04M | $756.98M | $722.69M | -15.9% |
Options analytics
Put / call volume
0.74
Call-heavy session
Put / call open interest
0.47
Positioning, not flow
Max pain
25.00
-8.9% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
160
Contracts, this expiry
Put volume
118
Contracts, this expiry
Heaviest call OI
30.00
1.18K contracts
Heaviest put OI
25.00
916 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.01 | 0.00 | -100.0% |
| Mar 2026 | -0.02 | 0.00 | +100.0% |
| Dec 2025 | 0.10 | 0.28 | +168.7% |
| Sep 2025 | -0.14 | 0.08 | +158.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.02 | 10 | $255.61M | +17.9% |
| Next quarter | 0.11 | 10 | $294.17M | +0.4% |
| Current year | 0.13 | 11 | $1.03B | +26.7% |
| Next year | 0.36 | 11 | $1.22B | +18.5% |
Analyst targets & ownership
Mean target$29.08
High target$38.00
Low target$22.00
Implied upside5.35%
Analyst count13
ConsensusBUY
Strong buy / Buy1 / 9
Hold4
Sell / Strong sell0 / 0
Held by insiders48.79%
Held by institutions56.55%
Institutions holding344
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
30.43
-9.31% from price
SMA 20
29.13
-5.74% from price
SMA 50
24.99
+9.88% from price
SMA 100
20.90
+32.03% from price
SMA 200
21.23
+29.33% from price
EMA 12
29.48
-6.39% from price
EMA 26
28.23
-2.25% from price
EMA 50
25.84
+6.83% from price
RSI (14)
47.5
Neutral
MACD (12,26,9)
1.25
Hist -0.56
ATR (14)
1.90
6.90% of price
Realised vol 30D
68.9%
Annualised
Bollinger upper
34.46
20, 2σ
Bollinger lower
23.79
20, 2σ
50 / 200 cross
Golden
24.99 vs 21.23
Trend bias
Above 200
+29.33%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.31
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
68.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.8%
Peak to trough
Max drawdown 5Y
-63.0%
Peak to trough
ATR 14
1.90
6.90% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
13.33M
Prior 14.95M
Change vs prior
-10.9%
Shorts covering
% of float
11.58%
Elevated
% of shares out
4.72%
Against total outstanding
Days to cover
2.6
Liquid
Float
134.87M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | UBS | INITIATED | — | Neutral |
| Aug 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 2, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 8, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 8, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 8, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 13, 26 | Jefferies | INITIATED | — | Buy |
| Apr 10, 26 | Piper Sandler | INITIATED | — | Neutral |
| Apr 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Mar 13, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-08-05
Trading Registrations
8-A12B · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-04-02
Headlines
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Investor's Business Daily · 5d ago
Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
PR Newswire · 8d ago
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
Investor's Business Daily · 15d ago
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
Zacks · 19d ago
Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
TIKR · 19d ago
Caris Life Sciences Insider Sold Shares Worth $12,132,080, According to a Recent SEC Filing
MT Newswires · 19d ago
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
GlobeNewswire · 21d ago
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Zacks · 21d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.